Results 191 to 200 of about 459,076 (282)

AFF4 Loss Compromises Osteogenesis of Orofacial Mesenchymal Stem Cells During Alveolar Bone Repair via AMPK‐Mediated Mitophagy

open access: yesCell Proliferation, EarlyView.
Compromised alveolar socket healing following tooth extraction upon Aff4 knockout is caused by suppressed osteogenic capacity of orofacial mesenchymal stem cells, which results from defective AMPK‐mediated mitophagy. ABSTRACT Repair of maxillofacial bone defects presents significant clinical challenges.
Li Zhu   +7 more
wiley   +1 more source

Active framing of health communication to and about individuals with non‐communicable diseases

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims To systematically document how individuals in vulnerable positions with diabetes or other non‐communicable diseases (NCD) are portrayed in texts from Danish health care institutions. Methods Our dataset consists of texts from Steno Diabetes Center Sjælland (SDCS) and 10 other Danish institutions related to diabetes and/or health care.
Katrine Ursbak   +4 more
wiley   +1 more source

DiaActive protocol: A randomized controlled trial of cognitive‐motor multicomponent exercise to reduce fall rate in older adults with diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Introduction Older adults with diabetes have an increased risk of falls due to neuropathy, impaired bone health and cardiovascular disease, resulting in significant morbidity and mortality. Conventional fall‐prevention programmes primarily target strength and balance, while cognitive‐motor integration, essential for safe mobility in complex ...
Aksayan Arunanthy Mahalingasivam   +4 more
wiley   +1 more source

Real‐world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

open access: yesDiabetic Medicine, EarlyView.
Abstract Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Jack E. Carruthers   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy